Company intelligence / Profile preview
Sanbe Farma
- Ownership
- Private
- Employees
- ~8000
- Development stage
- Commercial
Overview
Sanbe Farma operates multiple cGMP-approved manufacturing plants producing a wide range of generic pharmaceuticals and specialty products. The company has achieved international certifications including GCC approval for its oncology plant. It exports to over 20 countries and maintains a strong presence in Indonesia’s prescription drug market with several top-selling ethical products. No specific clinical trial results are published.
- Therapeutic areas
- OncologyMetabolic DisordersOphthalmologyInfectious Diseases
- Modalities
- Small molecules (oral solids/liquids/injectables)sterile injectables (LVP/SVP)oncology drugs/anticancer productsbiosimilars and injectable hormones in development
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Sanbe Farma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanbe Farma.